Robin Jones, MBBS, MRCP, MD, Royal Marsden NHS Foundation Trust, London, UK, discusses 3 salient trials in the realm of rare sarcoma treatment: P10015/SARC033 (NCT03148275), a Phase II trial investigating the efficacy of the MEK inhibitor trametinib in advanced epithelioid hemangioendothelioma (EHE), SPEARHEAD-1 (NCT04044768), a phase II trial investigating the efficacy of specific peptide enhanced affinity receptor (SPEAR) T-cells in MAGE-A4-positive advanced synovial and myxoid liposarcoma, and APROMISS (NCT03016819), a phase III trial of the multi-tyrosine kinase inhibitor anlotinib versus dacarbazine in advanced synovial sarcoma. These trials fill gaps in the data and show that late-stage trials are possible in rare sarcoma cell types. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
